Macrogenics Inc MGNX
News
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program
FDA Lifts Hold on Macrogenics Gynecological Cancer Treatment Trial
MacroGenics Study on Pause After Safety Issues

